Nutrition powder composition helpful for maintaining healthy level of blood sugar and blood fat as well as preparation method and application of nutrition powder composition

Abstract

The invention provides a nutritional powder composition helpful for maintaining the healthy level of blood sugar and blood fat. The nutritional powder composition is prepared from the following raw materials in parts by weight: 6.5-10.5 parts of tartary buckwheat bran, 0-2.6 parts of tartary buckwheat sprouts, 1.6 parts of konjak, 0.2 part of tremella, 0.3-3.3 parts of inulin, 0.3 part of dextrin, 0.05 part of lotus leaves and 0-4 parts of mung beans. The invention also provides a preparation method and application of the nutrition powder composition. The raw material is selected from high-quality tartary buckwheat which is planted in a pollution-free manner at a high altitude of 2000m or above in Daanshan Mountain, and is rich in active ingredients such as flavone and functional dietary fibers. The formula and proportion of the nutrition powder composition provided by the invention are richer and more reasonable, and the addition amount of the tartary buckwheat bran is reduced to relieve the bitter taste and improve the taste, so that the nutrition powder composition maintains good biological activity on the premise of being more easily accepted by consumers. The nutrition powder composition provided by the invention has a certain effect on maintaining the health level of blood fat and blood sugar, and the raw materials are compatible to play a synergistic effect. The nutrition powder composition provided by the invention can be used as a raw material of functional food and can also be directly eaten.

Description

Technical Field

[0001] The present invention relates to a nutritional powder composition helpful for maintaining healthy levels of blood glucose and blood lipids, and a preparation method and application thereof. Background Art

[0002] "Glucolipid metabolism disease" is a disease characterized by disorders of glucose and lipid metabolism, caused by genetics, environment and mental conditions. The clinical manifestations include one or several diseases such as hyperglycemia, hyperlipidemia, non-alcoholic fatty liver, atherosclerosis, etc. occurring simultaneously, and the glucolipid metabolism disorder is a lifelong disease, which is difficult to cure once suffered. The main clinical treatment adheres to two goals. The short-term goal is to control the increase of blood glucose and blood lipids and related metabolic disorders to eliminate the symptoms of glucolipid metabolism disorder and prevent more serious metabolic disorders from occurring. The long-term goal is to prevent or delay the occurrence and development of glucolipid metabolism disorder and its chronic complications through good metabolic control. Studies have shown that increasing the consumption of coarse grains, fruits and vegetables in the diet and reducing the intake of oils and sugars can effectively prevent glucolipid metabolism disorder, and dietary active ingredients play a key role in promoting human health. Therefore, dietary active ingredients have received great attention from nutritionists, food scientists and consumers.

[0003] Buckwheat belongs to the genus Fagopyrum of the Polygonaceae family and is a special coarse grain with both food and medicine uses. Buckwheat has high nutritional, health care and therapeutic values. Buckwheat is not only rich in nutrients, but also contains highly active proteins, active polypeptides, functional pectin-like dietary fibers, resistant starch, phenolic acids and other bioflavonoid active substances that other cereal crops do not have, and has the effects of reducing blood lipids, reducing obesity, antioxidant, anti-inflammatory, anti-diabetic and immunomodulation, etc., and has broad development prospects in the field of functional health foods. However, due to the special bitterness and taste of buckwheat, a large part of consumers cannot accept it. Therefore, there is an urgent need to develop a buckwheat nutritional powder composition with both good health care functions and better taste.

[0004] CN202011157062.5, Invention Name: A Buckwheat Flavonoid High-Fiber Powder and Its Preparation Method, provides a buckwheat flavonoid high-fiber powder and its preparation method to solve the problems of low nutritional value and single function of buckwheat powder in the prior art. The present invention includes the following raw materials in parts by weight: 95-105 parts of buckwheat husk powder, 4-6 parts of konjac powder, 4-6 parts of resistant dextrin, 3-5 parts of wolfberry, 2-4 parts of lotus leaf, 1-3 parts of rose, 1-3 parts of chrysanthemum powder, 0.5-1 part of truffle, 3-5 parts of tremella. The present invention uses buckwheat cortex powder, which contains more nutritional active substances such as flavonoids and dietary fibers than buckwheat powder, and improves the nutritional and health value of food.

[0005] CN202011157083.7, Invention Title: A Tartary Buckwheat Flavonoid High-Fiber Powder, provides a tartary buckwheat flavonoid high-fiber powder to solve the problems of low nutritional value and single function of tartary buckwheat powder in the prior art. The present invention includes the following raw materials in parts by weight: 95 - 105 parts of tartary buckwheat husk powder, 4 - 6 parts of konjac powder, 4 - 6 parts of resistant dextrin, 3 - 5 parts of wolfberry, 2 - 4 parts of lotus leaf, 1 - 3 parts of rose, 1 - 3 parts of chrysanthemum powder, 0.5 - 1 part of truffle, 3 - 5 parts of tremella. The present invention uses tartary buckwheat cortex powder, which contains more nutritional active substances such as flavonoids and dietary fiber than tartary buckwheat powder, improving the nutritional and health value of the food.

[0006] Currently, the publicly available tartary buckwheat nutritional powders are all ordinary foods with unclear health care effects. Moreover, due to the excessive addition of tartary buckwheat husk powder in the formula, the nutritional powder tastes bitter and has poor palatability. The single effect is subjectively judged based on sensory evaluation and consumer feedback, and the corresponding health care functions are not involved. Summary of the Invention

[0007] The present invention provides a nutritional powder composition, a preparation method and an application thereof, which are helpful for maintaining the healthy levels of blood sugar and blood lipids.

[0008] The present invention provides a nutritional powder composition, which is prepared from the following raw materials in weight ratio:

[0009] 6.5 - 10.5 parts of tartary buckwheat bran, 0 - 2.6 parts of tartary buckwheat sprouts, 1.6 parts of konjac, 0.2 part of tremella, 0.3 - 3.3 parts of inulin, 0.3 part of dextrin, 0.05 part of lotus leaf, 0 - 4 parts of mung bean.

[0010] Preferably, it is prepared from the following raw materials in weight ratio:

[0011] 7.5 parts of tartary buckwheat bran, 1.6 parts of konjac, 0.2 part of tremella, 3.3 parts of inulin, 0.3 part of dextrin, 0.05 part of lotus leaf;

[0012] Or,

[0013] 6.5 parts of tartary buckwheat bran, 1.6 parts of konjac, 0.2 part of tremella, 0.3 part of inulin, 0.3 part of dextrin, 0.05 part of lotus leaf, 4 parts of mung bean;

[0014] Or,

[0015] 6.5 parts of tartary buckwheat bran, 2.6 parts of tartary buckwheat sprouts, 1.6 parts of konjac, 0.2 part of tremella, 1.7 parts of inulin, 0.3 part of dextrin, 0.05 part of lotus leaf.

[0016] Among them, the dextrin is resistant dextrin.

[0017] The present invention provides a method for preparing a nutritional powder composition helpful for maintaining healthy levels of blood glucose and blood lipids, which comprises the following steps:

[0018] a. Take tartary buckwheat bran, powder it, stir-fry it, then add konjac powder and tremella powder and stir-fry again. After stir-frying, add lotus leaf powder and cool to room temperature;

[0019] b. Add inulin, dextrin, mung bean powder, and tartary buckwheat sprout powder to the powder obtained after step a, mix and stir;

[0020] c. Ultra-finely pulverize to obtain the product.

[0021] Preferably, the stir-frying temperature in step a is 190 °C; the stir-frying time of tartary buckwheat bran powder is 40 minutes; the stir-frying time after adding konjac powder and tremella powder is 20 minutes.

[0022] The present invention provides the use of the above-mentioned nutritional powder composition in the preparation of a health food helpful for maintaining a healthy level of blood lipids (cholesterol / triglyceride).

[0023] The present invention provides the use of the above-mentioned nutritional powder composition in the preparation of a health food helpful for maintaining a healthy level of blood glucose (fasting blood glucose / glucose tolerance).

[0024] The present invention uses tartary buckwheat bran as the main raw material, and through a unique formula and processing technology, obtains a nutritional powder composition with the function of assisting in maintaining healthy levels of blood glucose and blood lipids. This nutritional powder composition can be directly applied in various functional foods such as meal replacement powders, buckwheat flour, noodles, pastries, etc., providing a new direction and theoretical basis for the development of functional foods from tartary buckwheat.

[0025] The raw materials of the present invention are selected from high-quality tartary buckwheat grown in pollution-free areas at an altitude of over 2000 meters in Daliang Mountain, which is rich in active ingredients such as flavonoids and functional dietary fibers. The formula and ratio of the nutritional powder composition provided by the present invention are richer and more reasonable, and the addition amount of tartary buckwheat bran is reduced to reduce bitterness and improve the taste, so that the nutritional powder composition maintains good hypoglycemic and lipid-lowering activities while being more acceptable to consumers. The nutritional powder composition provided by the present invention has a certain effect on maintaining healthy levels of blood lipids and blood glucose, and the raw material compatibility plays a synergistic effect. The nutritional powder composition provided by the present invention can be used as a raw material for functional foods or can be directly eaten. Description of the Drawings

[0026] Figure 1Effects of nutritional powder compositions with different formulations on body weight (A), fasting blood glucose (B), glucose tolerance: blood glucose value (C) under OGTT and area under the glucose curve value (D) under OGTT, fasting insulin (E), and insulin resistance (F) in rats (NC (blank control group), MC (model control group), Y1 - Y4 (control groups of different formulation samples), H1 - H4 (high - dose groups of different formulations), L1 - L4 (low - dose groups of different formulations); different letters (a - f) represent significant differences in data between different groups (p < 0.05, n = 6));

[0027] Figure 2 Effects of nutritional powder compositions with different formulations on total cholesterol (A), triglyceride (B), low - density lipoprotein (C), and high - density lipoprotein (D) in rat serum (NC (blank control group), MC (model group), Y1 - Y4 (control groups of different formulation samples), H1 - H4 (high - dose groups of different formulations), L1 - L4 (low - dose groups of different formulations); different letters (a - g) represent significant differences in data between different groups (p < 0.05, n = 6));

[0028] Figure 3 Effects of nutritional powder compositions with different formulations on liver index (A) and epididymal fat index (B) in rats (NC (blank control group), MC (model control group), Y1 - Y4 (control groups of different formulation samples), H1 - H4 (high - dose groups of different formulations), L1 - L4 (low - dose groups of different formulations); different letters (a - f) represent significant differences in data between different groups (p < 0.05, n = 6)). Detailed implementation methods

[0029] Example 1 Preparation of the nutritional powder composition of the present invention:

[0030] Respectively, place tartary buckwheat bran powder (ground through 80 - mesh sieve), konjac powder, and tremella powder in an oven at 160 °C for 35 min, 8 min, and 8 min; place tartary buckwheat sprout powder in an oven at 150 °C for 16 min.

[0031] Ingredient preparation: Prepare different raw materials according to different ratios. The formulations of the four nutritional powder compositions are as follows in the table:

[0032] Table 1 Raw material ratios of nutritional powder compositions with different formulations

[0033]

[0034]

[0035] Stir-frying: Set the temperature to 190°C and add the raw materials according to the above formula. First, stir-fry the tartary buckwheat bran powder for 40 minutes until there is no water vapor. After green smoke appears, add konjac powder and tremella powder and stir-fry for another 20 minutes. Then add lotus leaf powder and pour it into a clean cold plate to cool to room temperature;

[0036] Mixing: Add inulin, resistant dextrin, mung bean powder, and tartary buckwheat sprout powder to the stir-fried raw materials, mix well, transfer to a blender and stir for 2 minutes until evenly mixed, and then take out and wait for ultrafine grinding;

[0037] Ultrafine grinding: Prepare for mechanical operation according to the operating procedures of the ultrafine powder machine. Set the motor frequency modulation pointer according to the mesh number of the ultrafine powder for ultrafine grinding, and perform ultrafine grinding on the evenly mixed sample;

[0038] Packaging: Carry out packaging according to the operating procedures of the packaging machine;

[0039] The beneficial effects of the nutritional powder composition of the present invention are demonstrated by the following ergonomic experiments.

[0040] Test Example 1 Efficacy Test of the Nutritional Powder Composition of the Present Invention

[0041] 1. Animal grouping and modeling method:

[0042] Purchase SPF male SD rats, 5 - 6 weeks old, weighing 150 ± 20 g. The rats were fed adaptively for 5 days, fasted for 3 - 4 h, tail blood was taken, and the fasting blood glucose was measured, as well as the blood glucose levels at 0.5 h and 2 h after administering 2.5 g / kg BW glucose, which served as the basic values for grouping the animals in this batch. Based on the blood glucose levels at 0 h and 0.5 h, they were divided into 14 groups, namely a blank control group (NC) and 4 sample control groups. The sample control groups were given maintenance feed and were respectively gavaged with high-dose (8 g / kg BW) test samples. The sample control groups were the control group of formula 1 (Y1), the control group of formula 2 (Y2), the control group of formula 3 (Y3), and the control group of formula 4 (Y4); a model control group (MC) and 8 test sample groups. The test sample groups were divided into high-dose groups and low-dose groups. The four high-dose groups were respectively gavaged with 4 high-dose (8 g / kg BW) test samples, numbered H1 (high-dose group of formula 1), H2 (high-dose group of formula 2), H3 (high-dose group of formula 3), and H4 (high-dose group of formula 4); the four low-dose groups were respectively gavaged with 4 low-dose (4 g / kg BW) test samples, numbered L1 (low-dose group of formula 1), L2 (low-dose group of formula 2), L3 (low-dose group of formula 3), and L4 (low-dose group of formula 4). Each group had 10 SD rats. After the adaptive feeding ended, the blank control group (NC) and the 4 sample control groups (Y1, Y2, Y3, Y4) were not treated. The 8 high- and low-dose groups (H1 - H4 and L1 - L4) were gavaged with test samples at different concentrations. The model control group (MC) was given the same volume of solvent for 33 consecutive days. After each group was fed with maintenance feed for 1 week, the model control group (MC) and the 8 high- and low-dose test sample groups (H1 - H4 and L1 - L4) were switched to high-calorie feed. After feeding for 3 weeks, the model control group and the 8 high- and low-dose test sample groups (H1 - H4 and L1 - L4) were fasted for 24 hours (water was not restricted), and alloxan was injected intraperitoneally at 105 mg / kg BW, with an injection volume of 1 mL / 100 g body weight. After the injection, they continued to be fed with high-calorie feed for 3 - 5 days, and the experiment ended.

[0043] 2. Determination of related indicators:

[0044] 2.1 Measurement of rat body weight

[0045] Record the body weight data at the same fixed time every day.

[0046] 2.2 Determination of rat fasting blood glucose and glucose tolerance

[0047] Animals in each group were fasted for 3 - 4 hours, and tail blood was taken to measure the fasting blood glucose using a blood glucose meter, i.e., the blood glucose value before giving glucose (0 hour). The high and low dose groups of the test sample were given test samples at different concentrations, the sample control group was given the high dose of the test sample, the model control group was given the same volume of solvent, and the blank control group was not treated. After 15 - 20 minutes, each group was orally administered 2.5 g / kg BW of glucose, and the blood glucose values of each group at 0.5 and 2 hours after giving glucose were measured. If the blood glucose value of the model control group at 0.5 hour ≥ 10 mmol / L, or the blood glucose increased or the area under the blood glucose curve increased at any time point of 0.5 hour and 2 hours in the model control group, and there was a significant difference compared with the blank control group, it was determined that the model of glucose metabolism disorder was established. On this basis, the changes in fasting blood glucose, blood glucose after giving glucose (0.5, 2 hours), and the area under the blood glucose curve at 0, 0.5, and 2 hours in the model control group and the test sample group were observed.

[0048]

[0049] 2.3 Determination of insulin level and insulin resistance in rats

[0050] Animals in each group were fasted for 3 - 4 hours, and the fasting serum insulin level was measured according to the instructions of the commercially available kit. The insulin resistance index was calculated according to the following formula.

[0051]

[0052] 2.4 Determination of blood lipid - related indexes in rats

[0053] Animals in each group were fasted for 3 - 4 hours, and the levels of triglyceride, total cholesterol, low - density lipoprotein, and high - density lipoprotein in the serum were measured according to the instructions of the commercially available kit. If the serum cholesterol or triglyceride in the model control group increased significantly and there was a significant difference compared with the blank control group, it was determined that the model of lipid metabolism disorder was established. On this basis, the changes in blood lipids in the model control group and the test sample group were observed.

[0054] 2.5 Determination of organ index in rats

[0055] Animals in each group were fasted for 3 - 4 hours, the liver and epididymal fat of the rats were collected and weighed, and the organ index was calculated according to the following formula:

[0056]

[0057] 3. Experimental results

[0058] 3.1 Effects of four nutritional powder compositions on the body weight of rats

[0059] Such as Figure 1As shown in Figure A, before the experiment, the body weights of rats in each group were similar and there were no significant differences. After 4 weeks of intervention with a high-fat diet, compared with the blank control group (NC), there was no statistical difference in the body weight of rats in the sample control group (high-dose test sample), indicating that the four nutritional powder compositions had no effect on the body weight of normal animals. The weight gain of rats in the model control group (MC) was significantly higher than that of the blank control group, indicating that the obesity rat model induced by long-term high-fat diet was established. Compared with the model control group, a body weight difference appeared in the test sample group on the 11th day. At the 30th day (after injecting alloxan), the body weights of rats in the high- and low-dose groups of the 4 test samples were lower than those of the model control group, indicating that the four nutritional powder compositions could all slow down the body weight gain of rats to a certain extent. After injecting alloxan, the body weights of rats in the model control group and the high- and low-dose groups of the test samples all decreased, but the rate of body weight loss in the high- and low-dose groups of the test samples was lower than that of the model control group, indicating that the four nutritional powder compositions might all have a certain weight loss and anti-diabetic effect.

[0060] 3.2 Effects of the four nutritional powder compositions on the blood glucose level of rats

[0061] Fasting blood glucose is an important indicator for type II diabetic patients. After 33 days of intervention with the four nutritional powder compositions, the fasting blood glucose of rats was measured. The results of the present invention are shown in Table 2 and Figure 1 Figure B. Compared with the blank control group (fasting blood glucose value was 4.40 mmol / L), there was no statistical difference in the fasting blood glucose value (4.02 - 4.35 mmol / L) of the sample control group (high-dose test sample), indicating that the four nutritional powder compositions had no significant effect on the blood glucose level of normal animals; compared with the blank control group, the blood glucose level of the model control group (22.23 mmol / L) increased significantly (p < 0.05), indicating that the rat model of glucose metabolism disorder was successfully established. Compared with the model control group, the fasting blood glucose levels of the high- and low-dose groups of the four test samples decreased (10.05 - 15.88 mmol / L) and were statistically significant (p < 0.05), indicating that the results of the fasting blood glucose index of the four nutritional powder compositions were positive.

[0062] 3.3 Effects of the four nutritional powder compositions on the glucose tolerance of rats

[0063] The OGTT was used to evaluate the response ability of the test animals to acute hyperglycemia. As shown in Table 2, Figure 1As shown in Figures C and 1D, the rats in the model control group had the highest blood glucose values at each blood glucose measurement point. At the same time, compared with the blank control group (14.73 mmol / L min), the area under the glucose curve of the model control group (52.26 mmol / L min) was significantly increased (p < 0.05); compared with the model control group, the area under the glucose curve of the high and low dose groups of the four test samples (30.55 - 41.94 mmol / L min) decreased and was statistically significant (p < 0.05), and the results of the glucose tolerance index of the four nutritional powder compositions were determined to be positive.

[0064] 3.4 Effects of the four nutritional powder compositions on rat insulin levels and insulin resistance

[0065] As shown in Table 2 and Figure 1 E, compared with the blank control group and the test sample group, the fasting insulin level of the model control group (8.76 μIU / mL) was significantly lower than that of the blank control group (11.30 μIU / mL) (p < 0.05); compared with the model control group, the high and low dose groups of the four test samples could all regulate the secretion of rat insulin. In addition, we also calculated the insulin resistance levels of rats in each group (Table 2 and Figure 1 F). Compared with the blank control group, the insulin resistance of the model control group was significantly increased (p < 0.05); compared with the model control group, the insulin resistance levels of the high dose groups of the test samples were all significantly decreased (p < 0.05), indicating that the four nutritional powder compositions could all improve the sensitivity of rats to insulin.

[0066] Table 2 Effects of nutritional powder compositions with different formulas on rat blood glucose levels

[0067]

[0068]

[0069] NC (blank control group), MC (model control group), Y1 - Y4 (control groups with different formulas), H1 - H4 (high dose groups with different formulas), L1 - L4 (low dose groups with different formulas); different letters (a - f) represent significant differences in data between different groups (p < 0.05, n = 6)

[0070] 3.5 Effects of the four nutritional powder compositions on rat blood lipid levels

[0071] As shown in Table 3 and Figure 2As shown in Figures A to 2D, the serum total cholesterol, triglyceride, and low-density lipoprotein of the rats in the model control group were significantly higher than those in the blank control group (p < 0.05), reaching 5.53 mmol / L, 3.62 mmol / L, and 1.85 mmol / L respectively. However, the high-density lipoprotein level of the rats in the model control group decreased significantly to 0.38 mmol / L (p < 0.05), indicating that the lipid metabolism disorder model in rats was established. Compared with the model control group, both the high-dose and low-dose groups of the test sample significantly reduced the total cholesterol level in rats (3.02 - 4.19 mmol / L) (p < 0.05), both the high-dose and low-dose groups of the test sample reduced the triglyceride level in rats (2.17 - 3.35 mmol / L), both the high-dose and low-dose groups of the test sample reduced the low-density lipoprotein level (1.43 - 1.78 mmol / L), and significantly increased the high-density lipoprotein level in rats (0.52 - 0.66 mmol / L). Based on the above results, it can be determined that the lipid-lowering index of the four nutritional powder compositions is positive.

[0072] Table 3 Effects of Nutritional Powder Compositions with Different Formulas on Blood Lipid Levels in Rats

[0073]

[0074] NC (blank control group), MC (model control group), Y1 - Y4 (control groups of different formula samples), H1 - H4 (high-dose groups of different formulas), L1 - L4 (low-dose groups of different formulas); different letters (a - g) represent significant differences in data between different groups (p < 0.05, n = 6) 3.6 Effects of Four Nutritional Powder Compositions on Organ Indexes of Rats

[0075] The liver and epididymal fat indexes of rats in each group are shown in Table 4 and Figure 3 As shown, compared with the blank control group (24.97 mg / g), the liver index of rats in the model control group (42.90 mg / g) increased significantly (p < 0.05); compared with the model control group, the liver indexes of rats in the high-dose and low-dose groups of the test sample (36.43 - 39.83 mg / g) decreased significantly (p < 0.05). Compared with the blank control group of rats (7.30 mg / g), the epididymal fat index of rats in the model control group (12.01 mg / g) increased significantly (p < 0.05); compared with the model control group, the epididymal fat indexes of rats in the high-dose and low-dose groups of the test sample (9.25 - 12.21 mg / g) were down-regulated to a certain extent, indicating that the intervention of the four nutritional powder compositions would normalize the organ indexes.

[0076] Table 4 Effects of Nutritional Powder Compositions with Different Formulas on Organ Index Levels in Rats

[0077]

[0078] NC (blank control group), MC (model control group), Y1 - Y4 (control groups of different formula samples), H1 - H4 (high - dose groups of different formulas), L1 - L4 (low - dose groups of different formulas); different letters (a - f) represent significant differences in data between different groups (p < 0.05, n = 6)

[0079] The above experimental results show that different nutritional powder compositions can all assist in maintaining the normal levels of blood glucose and blood lipids in rats. Specifically: The weight gain of rats in the high - and low - dose groups of the test samples was significantly controlled, indicating that different nutritional powder compositions can play a role in regulating the body weight of rats; The fasting blood glucose, insulin resistance, and area under the glucose curve values of rats in the high - and low - dose groups of the test samples were significantly lower than those of the model control group (p < 0.05), while the fasting serum insulin level of rats in the high - and low - dose groups of the test samples was significantly higher than that of the model control group (p < 0.05), confirming that different nutritional powder compositions can improve the glucose metabolism disorder in rats induced by high - fat diet and alloxan, thus maintaining the normal blood glucose level of rats; The total cholesterol and triglyceride levels of rats in the high - and low - dose groups of the test samples were significantly decreased (p < 0.05), while the high - density lipoprotein was significantly increased (p < 0.05), confirming that different nutritional powder compositions can significantly improve the lipid metabolism disorder caused by high - fat diet, thus maintaining the normal blood lipid level of rats; Finally, the liver index and epididymal fat index of rats in the high - and low - dose groups of the test samples were significantly decreased, also indicating that different nutritional powder compositions can regulate the lipid metabolism disorder induced by high - fat diet. In view of the above results, it can be determined that all four nutritional powders are helpful in maintaining the healthy levels of blood glucose and blood lipids, and the animal experiment results are positive. Especially for Formulas 1 - 3, by reducing the amount of tartary buckwheat bran, the taste of the nutritional powder composition is improved while maintaining good biological activity.

Claims

1. A nutritional powder composition that helps maintain healthy levels of blood sugar and blood lipids, characterized in that: It is prepared from the following raw materials in the following weight ratios: 6.5 - 10.5 parts of tartary buckwheat bran, 0 - 2.6 parts of tartary buckwheat sprouts, 1.6 parts of konjac, 0.2 parts of tremella, 0.3 - 3.3 parts of inulin, 0.3 parts of dextrin, 0.05 parts of lotus leaf, 0 - 4 parts of mung bean.

2. The nutritional powder composition according to claim 1, which helps to maintain healthy levels of blood glucose and blood lipids, is characterized in that: It is prepared from the following raw materials in the following weight ratios: 7.5 parts of tartary buckwheat bran, 1.6 parts of konjac, 0.2 parts of tremella, 3.3 parts of inulin, 0.3 parts of dextrin, 0.05 parts of lotus leaf; Or, 6.5 parts of tartary buckwheat bran, 1.6 parts of konjac, 0.2 parts of tremella, 0.3 parts of inulin, 0.3 parts of dextrin, 0.05 parts of lotus leaf, 4 parts of mung bean; Or, 6.5 parts of tartary buckwheat bran, 2.6 parts of tartary buckwheat sprouts, 1.6 parts of konjac, 0.2 parts of tremella, 1.7 parts of inulin, 0.3 parts of dextrin, 0.05 parts of lotus leaf.

3. The nutritional powder composition according to claim 1 or 2, which helps to maintain healthy blood glucose and blood lipid levels, is characterized in that: The dextrin described is resistant dextrin.

4. A method for preparing a nutritional powder composition according to any one of claims 1 to 3, which is helpful for maintaining a healthy blood glucose and blood lipid level, characterized in that: It includes the following steps: a. Take tartary buckwheat bran and powder it. After frying, add konjac powder and tremella powder and fry again. After frying, add lotus leaf powder and cool to room temperature; b. Add inulin, dextrin, mung bean powder, and tartary buckwheat sprout powder to the powder fried in step a, mix and stir; c. Ultra - micro pulverize to obtain.

5. The preparation method of the nutritional powder composition according to claim 4, which is helpful for maintaining healthy levels of blood glucose and blood lipids, is characterized in that: The frying temperature in step a is 190 °C; the frying time of tartary buckwheat bran powder is 40 minutes; the frying time after adding konjac powder and tremella powder is 20 minutes.

6. Use of the nutritional powder composition according to any one of claims 1 - 3 in the preparation of a health food helpful for maintaining a healthy level of blood lipids (cholesterol / triglyceride).

7. Use of the nutritional powder composition according to any one of claims 1 - 3 in the preparation of a health food helpful for maintaining a healthy level of blood glucose (fasting blood glucose / glucose tolerance).

Images